PE20120419A1 - 5-(2-{[6-(2,2-difuoro-2-feniletoxi) hexil] amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista de los receptores beta2 adrenergicos - Google Patents

5-(2-{[6-(2,2-difuoro-2-feniletoxi) hexil] amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista de los receptores beta2 adrenergicos

Info

Publication number
PE20120419A1
PE20120419A1 PE2011001314A PE2011001314A PE20120419A1 PE 20120419 A1 PE20120419 A1 PE 20120419A1 PE 2011001314 A PE2011001314 A PE 2011001314A PE 2011001314 A PE2011001314 A PE 2011001314A PE 20120419 A1 PE20120419 A1 PE 20120419A1
Authority
PE
Peru
Prior art keywords
phenyletoxy
difuoro
hydroxyquinolin
agonist
hexyl
Prior art date
Application number
PE2011001314A
Other languages
English (en)
Spanish (es)
Inventor
Thorsten Ruf
Montejo Eric Massana
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of PE20120419A1 publication Critical patent/PE20120419A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
PE2011001314A 2009-02-18 2010-02-18 5-(2-{[6-(2,2-difuoro-2-feniletoxi) hexil] amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista de los receptores beta2 adrenergicos PE20120419A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09382020A EP2221055A1 (en) 2009-02-18 2009-02-18 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function

Publications (1)

Publication Number Publication Date
PE20120419A1 true PE20120419A1 (es) 2012-05-09

Family

ID=40833525

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001314A PE20120419A1 (es) 2009-02-18 2010-02-18 5-(2-{[6-(2,2-difuoro-2-feniletoxi) hexil] amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista de los receptores beta2 adrenergicos

Country Status (32)

Country Link
US (2) US20120029014A1 (enExample)
EP (2) EP2221055A1 (enExample)
JP (1) JP2012518019A (enExample)
KR (1) KR20110123742A (enExample)
CN (2) CN102325530A (enExample)
AR (1) AR075432A1 (enExample)
AU (1) AU2010214854A1 (enExample)
CA (1) CA2749059C (enExample)
CL (1) CL2011002001A1 (enExample)
CO (1) CO6361939A2 (enExample)
CY (1) CY1114484T1 (enExample)
DK (1) DK2398473T3 (enExample)
EA (1) EA022442B1 (enExample)
EC (1) ECSP11011336A (enExample)
ES (1) ES2430596T3 (enExample)
HR (1) HRP20130917T1 (enExample)
IL (1) IL213979A0 (enExample)
ME (1) ME01757B (enExample)
MX (1) MX2011008577A (enExample)
MY (1) MY155657A (enExample)
NZ (1) NZ593727A (enExample)
PE (1) PE20120419A1 (enExample)
PL (1) PL2398473T3 (enExample)
PT (1) PT2398473E (enExample)
RS (1) RS52951B (enExample)
SG (2) SG173091A1 (enExample)
SI (1) SI2398473T1 (enExample)
TW (2) TW201031408A (enExample)
UA (1) UA103370C2 (enExample)
UY (1) UY32414A (enExample)
WO (1) WO2010094483A1 (enExample)
ZA (1) ZA201104654B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2668941A1 (en) * 2012-05-31 2013-12-04 Almirall, S.A. Novel dosage form and formulation of abediterol

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
ATE209938T1 (de) 1990-09-26 2001-12-15 Pharmachemie Bv Wirbelkammer-pulverinhalator
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
UA27961C2 (uk) 1992-12-18 2000-10-16 Шерінг Корпорейшн Інгалятор для порошкових ліків
EP1908488A3 (en) 1995-04-14 2008-04-16 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
AU719449B2 (en) 1995-06-21 2000-05-11 Astrazeneca Ab Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2265276B1 (es) * 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
FR2903168B1 (fr) * 2006-06-30 2008-08-22 Fayard Eliane Bruleur pour realiser la combustion de substances reputees difficilement combustibles
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY32297A (es) * 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico

Also Published As

Publication number Publication date
UA103370C2 (uk) 2013-10-10
DK2398473T3 (da) 2013-10-21
AR075432A1 (es) 2011-03-30
WO2010094483A1 (en) 2010-08-26
EP2398473B1 (en) 2013-07-24
AU2010214854A1 (en) 2011-07-21
PL2398473T3 (pl) 2013-12-31
RS52951B (sr) 2014-02-28
CY1114484T1 (el) 2016-10-05
US20120029014A1 (en) 2012-02-02
CN105326838A (zh) 2016-02-17
EA022442B1 (ru) 2016-01-29
EP2398473A1 (en) 2011-12-28
SG173091A1 (en) 2011-08-29
MY155657A (en) 2015-11-13
MX2011008577A (es) 2011-09-06
CN102325530A (zh) 2012-01-18
ZA201104654B (en) 2012-02-29
KR20110123742A (ko) 2011-11-15
NZ593727A (en) 2013-07-26
CA2749059A1 (en) 2010-08-26
US20140343097A1 (en) 2014-11-20
CL2011002001A1 (es) 2011-11-11
PT2398473E (pt) 2013-09-30
EA201101210A1 (ru) 2012-03-30
TW201031408A (en) 2010-09-01
HRP20130917T1 (hr) 2013-11-08
CA2749059C (en) 2017-08-01
HK1159990A1 (en) 2012-08-10
ME01757B (me) 2014-09-20
TW201442711A (zh) 2014-11-16
ECSP11011336A (es) 2011-10-31
ES2430596T3 (es) 2013-11-21
IL213979A0 (en) 2011-08-31
UY32414A (es) 2010-07-30
JP2012518019A (ja) 2012-08-09
SI2398473T1 (sl) 2013-11-29
EP2221055A1 (en) 2010-08-25
SG2014012827A (en) 2014-04-28
CO6361939A2 (es) 2012-01-20

Similar Documents

Publication Publication Date Title
PE20120419A1 (es) 5-(2-{[6-(2,2-difuoro-2-feniletoxi) hexil] amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista de los receptores beta2 adrenergicos
PE20081752A1 (es) Sal de napadisilato de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2-(1h)-ona como agonista del receptor adrenergico b2
UA105913C2 (uk) МЕЗИЛАТ 5-(2-{[6-(2,2-ДИФТОР-2-ФЕНІЛЕТОКСИ)ГЕКСИЛ]АМІНО}-1-ГІДРОКСІЕТИЛ)-8-ГІДРОКСИХІНОЛІН-2(1H)-ОНУ ЯК АГОНІСТ β2-АДРЕНЕРГІЧНОГО РЕЦЕПТОРА
SV2010003642A (es) Compuestos
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
PE20120420A1 (es) 5-(2-{[6-(2,2-difluoro-2-feniletoxihexil] amino}-1-hidroxietil)-8-hidroxiquinolin-2(ih)-ona como agonista de los receptores beta2 adrenergicos
ZA201008886B (en) Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
ZA201604499B (en) Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
CR20140433A (es) Nuevas formas cristalinas polimorficas de 5-(2-{[6-(2,2-difluoro -2-feniletoxi) hexil] amino}-1-(r)-hidroxietil)-8-hidroxiquinolin-2 (1h)-ona, heminapadisilato como agonista del receptor adrenergico b2
IT1391172B1 (it) Processo per la purificazione-addolcimento del gas naturale tramite dissociazione controllata degli idrati e uso degli stessi come separatori.
WO2013134080A3 (en) Improved method and compound for treatment of menopausal symptoms
UY34334A (es) Procedimento para preparar 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil] -amino}-1(R)-hidroxietil) -8-hidroxiquinolin-2(1H)-ona
MX2014004743A (es) Uso de derivados de aminoacetonitrilo contra endoparasitos.

Legal Events

Date Code Title Description
FC Refusal